Clinical Trials
2,311 trialsNCT00092222 2026-06-05
Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT01683279 2026-06-05
A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia
Seattle Children's Hospital
Phase 1 Active not recruiting
NCT01804686 2026-06-05
CAN3001
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT02981628 2026-06-05
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Children's Oncology Group
Phase 2 Recruiting
NCT03186118 2026-06-05
Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia
Seattle Children's Hospital
Phase 1 Active not recruiting
NCT03223610 2026-06-05
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT03258567 2026-06-05
Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT03460977 2026-06-05
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Pfizer
Phase 1 Recruiting
NCT03922724 2026-06-05
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT04747912 2026-06-05
Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
University of Chicago
Phase 2 Recruiting
NCT04840602 2026-06-05
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05053659 2026-06-05
Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma
Case Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT05363800 2026-06-05
Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Active not recruiting
NCT05421663 2026-06-05
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
Janssen Research & Development, LLC
Phase 1/2 Recruiting
NCT05424822 2026-06-05
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT05621291 2026-06-05
A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...
National Institutes of Health Clinical Center (CC)
Phase NA Recruiting
NCT05723055 2026-06-05
NAHL
University of Utah
Phase 2 Active not recruiting
NCT05748171 2026-06-05
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
Pfizer
Phase 2 Recruiting
NCT05784441 2026-06-05
A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT05963074 2026-06-05
TAILOR
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT06139406 2026-06-05
A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT06227026 2026-06-05
PRODIGY
University of Utah
Phase 1 Recruiting
NCT06284122 2026-06-05
MorningLyte
The Lymphoma Academic Research Organisation
Phase 3 Recruiting
NCT06381830 2026-06-05
Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma
The First Affiliated Hospital of Soochow University
Phase 2 Terminated
NCT06421155 2026-06-05
Brain MRF in Children, Adolescents and Young Adults With Acute Leukemia
Case Comprehensive Cancer Center
Phase NA Suspended
NCT06447987 2026-06-05
Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia
City of Hope Medical Center
Phase 1 Suspended
NCT06470438 2026-06-05
A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT06643221 2026-06-05
Allo-X
University of Arizona
Phase EARLY_PHASE1 Recruiting
NCT06660563 2026-06-05
A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL)
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT06765317 2026-06-05
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06788509 2026-06-05
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Janssen Research & Development, LLC
Phase 1 Enrolling by invitation
NCT06860594 2026-06-05
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
National Cancer Institute (NCI)
Phase 1 Suspended
NCT06904066 2026-06-05
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT07137494 2026-06-05
A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT07164469 2026-06-05
Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting
NCT07194980 2026-06-05
Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Fred Hutchinson Cancer Center
Phase 2 Recruiting
NCT07278856 2026-06-05
Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas
City of Hope Medical Center
Phase 1 Recruiting
NCT07295951 2026-06-05
A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT07302347 2026-06-05
MK-3475-G21
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT07308132 2026-06-05
A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT07328503 2026-06-05
CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT07524530 2026-06-05
Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Not yet recruiting
NCT07570173 2026-06-05
MK-1045-005
Merck Sharp & Dohme LLC
Phase 2/3 Recruiting
NCT07572136 2026-06-05
Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)
National Institutes of Health Clinical Center (CC)
Phase 1 Not yet recruiting
NCT07614022 2026-06-05
A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL)
Wake Forest University Health Sciences
Phase 1 Not yet recruiting
NCT07628634 2026-06-05
Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors
University of California, Irvine
Phase EARLY_PHASE1 Recruiting
NCT07628738 2026-06-05
A Prospective Clinical Study on Reduced-intensity Radiotherapy for Stage I/II Low-risk Nasal-type NK/T-cell Lymphoma Achieving Complete Remission After Chemotherapy
Ruijin Hospital
Phase 2 Recruiting
NCT07630545 2026-06-05
A Phase I Study in Healthy Volunteers and Parkinson's Disease (PD) Patients.
Mission Therapeutics
Phase 1 Recruiting
NCT01868451 2026-06-04
Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT03919240 2026-06-04
CAR-T Cell Therapy Targeting to CD19 for R/R ALL
The First Affiliated Hospital of Soochow University
Phase 1/2 Active not recruiting